Compare Arqit Quantum Inc (ARQQ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs Smith & Nephew plc — how do they compare? Arqit Quantum Inc trades at $17.8 (market cap $332.04M), while Smith & Nephew plc trades at $31.1 (market cap $12.69B). The key difference: Smith & Nephew plc is far larger — about 38.2× Arqit Quantum Inc's market cap, and Smith & Nephew plc pays a 2.55% dividend while Arqit Quantum Inc pays none. Which is the better fit depends on your goals.
| ARQQ | SNN | |
|---|---|---|
Market Cap | $332.04M | $12.69B |
Sector | Technology | Health |
52-Week High | $58.27 | $38.70 |
52-Week Low | $11.78 | $28.73 |
Enterprise Value | $305.35M | $15.46B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $19.08, down 6.79% today, with a bearish technical signal from moving averages. The company reported $530K revenue for 2025 but a net loss of $35.34M, with negative profit margins and high valuation ratios. Recent news highlights contract wins and 829% YoY revenue growth in H1 FY26, though earnings misses persist.
Outlook remains speculative given deep losses and high P/S of 275.84, but growth in quantum security deals offers potential. Key risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold, indicating cautious optimism amid fundamental challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
